CN103536602B - Medicine used for controlling pasteurella infection of livestock and poultry - Google Patents
Medicine used for controlling pasteurella infection of livestock and poultry Download PDFInfo
- Publication number
- CN103536602B CN103536602B CN201310482366.2A CN201310482366A CN103536602B CN 103536602 B CN103536602 B CN 103536602B CN 201310482366 A CN201310482366 A CN 201310482366A CN 103536602 B CN103536602 B CN 103536602B
- Authority
- CN
- China
- Prior art keywords
- sulfachlorpyridazine sodium
- compound
- sodium powder
- parts
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to compound sulfachlorpyridazine sodium powder, and specifically provides compound sulfachlorpyridazine sodium powder used for controlling pasteurella infection of livestock and poultry. 100 parts of the compound sulfachlorpyridazine sodium powder comprise 60 to 65 parts of sulfachlorpyridazine sodium, 2 to 4 parts of indometacin potassium, 10 to 25 parts of a suspending agent, 2 to 4 parts of a corrigent and the balance an acceptable carrier. The ingredients above are mixed and grinded so as to obtain the compound sulfachlorpyridazine sodium powder. The compound sulfachlorpyridazine sodium powder possesses accurate curative effects on pasteurellosis of a plurality of animals, and is suitable for popularization and application in livestock breeding. According to the preparation method, sulfachlorpyridazine sodium and indometacin potassium are used together, besides antisepsis and anti-inflammation effects, indometacin potassium is used as an antibacterial synergist of sulfachlorpyridazine sodium, so that synergistic effect is achieved, and pharmacological function of the main medicine is improved. Absorptivity of the compound sulfachlorpyridazine sodium powder, which can be taken orally, or mixed with feed for use, or dissolved in drinking water for use, is high; drug tolerance is difficult to be caused; the compound sulfachlorpyridazine sodium powder is safe to be used for protection, prevention and therapy in a long term. Palatability, fluidity and suspending water solubility are excellent; clinical administration methods are diverse; and the compound sulfachlorpyridazine sodium powder is convenient for clinical administration.
Description
The application is application number: 201210358062.0, and patent name is: the divisional application of the patent of invention of " a kind of preparation method of Compound Sulfachorpyrdazine Sodium Powder ", the original bill applying date: on JIUYUE 24th, 2012.
Technical field
The present invention relates to a kind of Compound Sulfachorpyrdazine Sodium Powder, also relate to the medicine of control poultry pasteurella infection.
Background technology
Prinzone (Squibb) antimicrobial spectrum is similar to sulfamonomethoxine, is one of sulphonamides that vivo bacteria corrosion action is the strongest, has comparatively high inhibition effect to most of gram positive bacteria and negative bacterium, and it is slower that antibacterial produces drug resistance to this medicine.Blood drug level is high, and acetyl rate is low, not easily produces crystalluria.
Bacillus pasteurii disease is a kind of septic infectious disease of the many animals caused by pasteurella multocida.When weather, seasonal variations, long-distance transport and the factor such as parasitic infection, malnutrition cause animal body resistance to reduce, Fit First animal respiratory and the interior existing pasteurellosis bacillus of tonsil will become strong toadstool and cause autogenous infection.In addition can because the feedstuff, water, air, utensil etc. polluted be through digestive tract, respiratory tract, wound and cause exogenous infection.Because infective agent ubiquity, the normal acute attack of primary disease, the sick fowl of most acute can without any symptom, and several lower wing of flapping suddenly falls down to the ground death, and affected animal is in the majority for age with children, and comparatively seriously, case fatality rate is high.
The medicine of the control poultry pasteurella infection needing a kind of effect more definite in prior art.Meanwhile, the Prinzone (Squibb) powder preparation of poultry pasteurella infection is not is not prevented and treated in prior art yet.
Summary of the invention
Main purpose of the present invention is to provide a kind of preparation method of the Compound Sulfachorpyrdazine Sodium Powder for preventing and treating poultry pasteurella infection.
The technical solution adopted in the present invention is: a kind of preparation method of Compound Sulfachorpyrdazine Sodium Powder, is characterized in that:
Formula:
Preparation process:
A, the suspending agent getting recipe quantity are pulverized, and cross 80 eye mesh screens, be then uniformly mixed after pulverizing, and check the opaque uniformity without decorative pattern without mottle, obtain A powder, for subsequent use; Usual incorporation time is about 15min;
B, the Prinzone (Squibb) getting recipe quantity, indomethacin potassium and correctives are pulverized, and cross 80 eye mesh screens, be then uniformly mixed after pulverizing, and the inspection opaque uniformity without mottle, obtains B powder without decorative pattern; Usual incorporation time is about 15min;
C, above-mentioned B powder added in A powder by the equivalent method of progressively increasing stir, then add enough other carriers acceptable and continue to be uniformly mixed, check that the opaque uniformity crosses 80 eye mesh screens without decorative pattern without after mottle, to obtain final product; Usual incorporation time is about 15min.
During subpackage, can fill in vinyon bottle, polyethylene plastic bag, loading amount comprises 100g, 200g, 500g etc.
Further, described correctives is sucrose and/or saccharin sodium.
Further, described suspending agent is one or more in silicon Bentonite, sodium citrate, sodium carboxymethyl cellulose.
Further, described suspending agent is the mixture of silicon Bentonite 5 ~ 10 parts, sodium citrate 5 ~ 10 parts, sodium carboxymethyl cellulose 3 ~ 5 parts.
Further, described acceptable carrier is anhydrous glucose or soluble starch.
Product prepared by the inventive method shows following technical advantage in practice:
1, there is definite curative effect to the Bacillus pasteurii disease of many animals, be suitable for promoting the use of in livestock culture.The present invention adopts Prinzone (Squibb) and indomethacin potassium compatibility to use, and while anti-inflammation, indomethacin potassium is as the Trimethoprim of Prinzone (Squibb), can produce the drug effect that synergism strengthens principal agent.Oral, mixed feeding, drinking-water absorb well and not easily produce drug resistance, long-term care Prevention and Curation use safety.
2, the Compound Sulfachorpyrdazine Sodium Powder of novel process technology preparation has good palatability, mobility and suspendible water solublity, ensures that this product clinical administration is various and convenient.Correctives can cover the bitterness of Prinzone (Squibb), indomethacin potassium completely, can be directly oral; The adjuvant of the selected suitable particle diameter of prescription makes finished product have good mobility, is convenient to Homogeneous phase mixing, and mixed fodder is fed also very safe; Meanwhile, this product is also dry suspension, easily topple over after dissolving, sedimentation slowly, jolting energy redispersion gently after sedimentation, and the size of suspended particles after dissolving remains unchanged in long-term storage in water.This in turn ensures effectiveness and the safety of drinking-water use.
The theoretical foundation of the product that the present invention obtains may be: technical scheme of the present invention has better played the effect of indomethacin potassium.Indomethacin (Indomethacin) has obvious potent effect to some antibiotic or antimicrobial drug.Because lung tissue is tissue basophil, when pulmonary is inflamed, the sulfa drugs of some antibiotic of indomethacin portability as high dose preferentially arrives infection site, and high concentration is gathered in inflammatory tissue cell peripheral, indomethacin can make sulfa drugs concentration in infected tissue improve 4 ~ 8 times, and after coupling, anti-infectives use amount can reduce by half and even can be only 1/4 of positive usual amounts.This Synergistic Mechanisms is different from the mechanism of action of trimethoprim.Indomethacin also has significant antiinflammatory, antipyretic and analgesic activity.Its antiinflammation is the strongest in anti-inflammation drugs.It is to pig height febrile illness antipyretic and anti-inflammatory, chicks thoracic cavity infection, duck infectious bronchitis and poultry pneumonia, hydrothorax and Combination pneumonia have significant adjuvant treatment effect, and this may have obviously potent relevant with antiinflammation with indomethacin.
Detailed description of the invention
The principal agent Prinzone (Squibb) (anhydride meter content is 99.8%) used in embodiment is purchased from Zhuhai Yuan Cheng medication chemistry company limited; Indomethacin potassium (anhydride meter content is 99.1%) is purchased from Ou Yi Shi Pharmaceutical Group Pharmaceutical Co; Soluble starch, anhydrous glucose, sucrose and saccharin sodium are purchased from Henan navigator's chemical products company limited; Silicon Bentonite, sodium citrate, sodium carboxymethyl cellulose (AR) are purchased from Hua Heng bio tech ltd of Jizhou City.
Embodiment one
1, formula
Prinzone (Squibb) 60g, indomethacin potassium 2g, silicon Bentonite 5g, sodium citrate 5g, sodium carboxymethyl cellulose 3g, saccharin sodium 2g, soluble starch 23g.
2: preparation method
The first step: get the silicon Bentonite of recipe quantity, sodium citrate, sodium carboxymethyl cellulose pulverize, cross 80 eye mesh screens after pulverizing, be then uniformly mixed 15min, obtain without the A powder of decorative pattern without mottle;
Second step: get the Prinzone (Squibb) of recipe quantity, indomethacin potassium and saccharin sodium and pulverize, crosses 80 eye mesh screens after pulverizing, is then uniformly mixed 15min, obtains without the B powder of decorative pattern without mottle;
3rd step: above-mentioned B powder is added in A powder by the equivalent method of progressively increasing and stirs, then add enough soluble starches and continue to be uniformly mixed 15min.Check and confirm that the opaque uniformity crosses 80 eye mesh screens without decorative pattern without after mottle, obtain Compound Sulfachorpyrdazine Sodium Powder.
Embodiment two
1, formula
Prinzone (Squibb) 62.5g, indomethacin potassium 3g, silicon Bentonite 7.5g, sodium citrate 7.5g, sodium carboxymethyl cellulose 4g, sucrose 3g, anhydrous glucose 12.5g.
2: preparation method: identical with method described in embodiment 1, only correctives saccharin sodium is changed to sucrose, other carrier being soluble starch is changed to anhydrous glucose.
Embodiment three
1, formula
Prinzone (Squibb) 65g, indomethacin potassium 4g, silicon Bentonite 10g, sodium citrate 10g, sodium carboxymethyl cellulose 5g, sucrose 4g, anhydrous glucose 2g.
2: preparation method: identical with method described in embodiment 1, only correctives saccharin sodium is changed to sucrose, other carrier being soluble starch is changed to anhydrous glucose.
The stability test of Compound Sulfachorpyrdazine Sodium Powder
1, materials and methods: the Compound Sulfachorpyrdazine Sodium Powder of Example 1-3, hot and humid high light Acceleration study is carried out according to " Chinese veterinary pharmacopoeia " version in 2010 annex medicine stability experimental technique, by commercially available back, place 6 months in the medicine stability experimental box (Chongqing immortality experimental apparatus factory) of temperature 40 ± 2 DEG C, relative humidity 75 ± 5%, illumination 4500 ± 500LX, sample respectively once 1st, 2,3,6 the end of month at experimental session, the character of powder, content, granularity, appearance uniform degree, sedimentation volume ratio, redispersibility are investigated.
2, result: as shown in Table 1, Compound Sulfachorpyrdazine Sodium Powder of the present invention is in accelerated test after 6 months, character, content, granularity, appearance uniform degree, sedimentation volume ratio, redispersibility have no significant change, have good stability, meet " Chinese veterinary pharmacopoeia " version in 2010 completely to the quality index requirement of dry suspension.
The Acceleration study result of table 1, Compound Sulfachorpyrdazine Sodium Powder of the present invention
Compound Sulfachorpyrdazine Sodium Powder is at veterinary clinic effect
1. materials and methods
1.1 medicine
Compound Sulfachorpyrdazine Sodium Powder of the present invention, adopts the embodiment of the present invention 2 product.
1.2 cases sources: technical staff in Hechuan, Tongliang County, the area such as Tongnan gather clinical in pasteurella infection natural occurrence case, is respectively duck infectious bronchitis 337 example, chicken pneumonia 3625 example, rabbit snuffles 284 example, piglet pleuropneumonia 235 example, chicken cholera 2780 example, baby swine paratyphoid 332 example, acute fibrinous pleurisy 101 example of cattle.
1.3 case diagnosis: with natural cases according to epidemiology, clinical symptoms, pathological change, Laboratory Diagnosed.Comprehensive analysis, is diagnosed as pasteurella infection case.
1.4 implementation processes: carry out case selection by this seminar technical staff and implement treatment, and log.
1.5 results judge
Usage and dosage: natural cases used by drinking-water is for oral administration, a secondary amounts, every 1kg body weight, pig, cattle 20 ~ 30mg, be used in conjunction 6; Chicken, duck, rabbit 20 ~ 30mg, be used in conjunction 4.Observe after one week, pay a return visit and record the state of an illness.
Cure: medication 3 ~ 4 future trouble poultry diseases disappear completely, and spirit, body temperature, appetite recover normal, and urine feces is normal.
Effective: medication 3 ~ 4 future trouble poultry diseases disappear substantially, and spirit, body temperature, appetite make moderate progress, and urine feces is normal.
Invalid: medication 4 future trouble poultry diseases do not disappear, and sb.'s illness took a turn for the worse or death, and urine stool colour, character are abnormal.
2. result: compound sulfamethoxazole methoxy pyridazine injection of the present invention has good therapeutic effect as can be seen from Table 2, more than 96.0% is reached to effective percentage such as duck infectious bronchitis, chicken pneumonia, rabbit snuffles, piglet pleuropneumonia, chicken cholera, baby swine paratyphoid, the acute fibrinous pleurisies of cattle, cure rate all more than 92%, and has specially good effect to chicken cholera, chicken pneumonia.
Table 2: Compound Sulfachorpyrdazine Sodium Powder clinical therapeutic efficacy statistical table of the present invention
Compound Sulfachorpyrdazine Sodium Powder of the present invention adopts Prinzone (Squibb) and the composite effect achieving enhancing evident in efficacy of indomethacin potassium.And the consumption of indomethacin potassium needs to be strict with in formula, can only select at this particular range.
For verifying this technique effect, carry out contrast test.
The formula of comparative example 1: Prinzone (Squibb) 62.5g, indomethacin potassium 1g, silicon Bentonite 7.5g, sodium citrate 7.5g, sodium carboxymethyl cellulose 4g, sucrose 3g, anhydrous glucose 14.5g.
The formula of comparative example 2: Prinzone (Squibb) 62.5g, indomethacin potassium 6g, silicon Bentonite 7.5g, sodium citrate 7.5g, sodium carboxymethyl cellulose 4g, sucrose 3g, anhydrous glucose 9.5g.
The formula of comparative example 3: Prinzone (Squibb) 62.5g, indomethacin potassium 10g, silicon Bentonite 7.5g, sodium citrate 7.5g, sodium carboxymethyl cellulose 4g, sucrose 3g, anhydrous glucose 5.5g.
Preparation method is identical with embodiment 1.
Implement the product of 2 and the product of comparative example 1,2,3, the curative effect being used for the treatment of pasteurella infection case by same usage and dosage is as shown in table 3, and visible formula of the present invention achieves significant technique effect.
The statistical effect table of table 3 product of the present invention and contrast product clinical treatment chicken pneumonia
Claims (3)
1. a Compound Sulfachorpyrdazine Sodium Powder, is characterized in that:
Formula is:
Described suspending agent is one or more in silicon Bentonite, sodium citrate, sodium carboxymethyl cellulose.
2. a kind of Compound Sulfachorpyrdazine Sodium Powder according to claim 1, is characterized in that: described correctives is sucrose and/or saccharin sodium.
3. a kind of Compound Sulfachorpyrdazine Sodium Powder according to claim 1, is characterized in that: described suspending agent is the mixture of silicon Bentonite 5 ~ 7.5 parts, sodium citrate 5 ~ 7.5 parts, sodium carboxymethyl cellulose 3 ~ 4 parts.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310482366.2A CN103536602B (en) | 2012-09-24 | 2012-09-24 | Medicine used for controlling pasteurella infection of livestock and poultry |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310482366.2A CN103536602B (en) | 2012-09-24 | 2012-09-24 | Medicine used for controlling pasteurella infection of livestock and poultry |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210358062.0A Division CN102860984B (en) | 2012-09-24 | 2012-09-24 | Method for preparing compound sulfachloropyridazine sodium powder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103536602A CN103536602A (en) | 2014-01-29 |
| CN103536602B true CN103536602B (en) | 2015-06-03 |
Family
ID=49960717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310482366.2A Expired - Fee Related CN103536602B (en) | 2012-09-24 | 2012-09-24 | Medicine used for controlling pasteurella infection of livestock and poultry |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103536602B (en) |
-
2012
- 2012-09-24 CN CN201310482366.2A patent/CN103536602B/en not_active Expired - Fee Related
Non-Patent Citations (3)
| Title |
|---|
| Ralph D.Feigin etal.Textbook of Pediatric Infectious Diseases.《Textbook of Pediatric Infectious Diseases》.2004,(第5版),第3013页. * |
| 吲哚美辛在畜禽疾病中的应用;徐艳;《养殖技术顾问》;20101231(第3期);第164页 * |
| 紫外分光光度法和永停滴定法测定复方磺胺氯达嗪钠粉的含量;聂斌等;《中国兽药杂志》;20061231;第40卷(第4期);52-54 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103536602A (en) | 2014-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112451517A (en) | Application of epigallocatechin 3-O- (3-O-methyl) gallate in preparing anti-coronavirus medicine | |
| CN102846641B (en) | Compound sulfachlorpyridazine sodium powder for preventing and treating pasteurella infection of livestock and poultry | |
| CN106176617B (en) | Amoxicillin soluble powder and preparation method thereof | |
| CN103054808B (en) | Tilmicosin dry suspension, method for preparing dry suspension and uses thereof | |
| CN104814931B (en) | A kind of olaquindox slow-releasing granules and its preparation method and application | |
| CN102860984B (en) | Method for preparing compound sulfachloropyridazine sodium powder | |
| CN103083347B (en) | Preparation method of albendazole/ivermectin powder for livestock | |
| CN108853025A (en) | A kind of Tilmicosin solid dispersions and preparation method thereof | |
| CN103239422A (en) | Preparation method of smellless coated enrofloxacin preparation | |
| CN103536602B (en) | Medicine used for controlling pasteurella infection of livestock and poultry | |
| CN103536601B (en) | Preparation method of medicine used for controlling pasteurella infection of livestock and poultry | |
| CN103126982A (en) | Novel veterinary medicament meglumine enrofloxacin injection and preparation method thereof | |
| CN103721240B (en) | Compound formulation for treating bacterial infection of digestive tract of livestock and poultry and preparation method of compound formulation | |
| CN102727596B (en) | A kind of Chinese herbal granules for preventing chicken coccidiasis and preparation method thereof | |
| CN107647114A (en) | A kind of method of pellet addition medicine | |
| CN103520267A (en) | Wettable experimental pullorum evapotranspiration and preparation method thereof | |
| CN106474132B (en) | Application of the Polaprezinc in preparation treatment or mitigation caused by radiotherapy and chemotherapy intestinal complications and irritable bowel syndrome drug | |
| US20190008967A1 (en) | Oil suspension of metronidazole | |
| CN107669700A (en) | A kind of medicine for treating ulcerative colitis and preparation method thereof | |
| CN103083414A (en) | Traditional Chinese medicine composition used for enhancing chicken immunity | |
| CN105560218A (en) | Use of resveratrol homologues in prevention and treatment on myelosuppression | |
| CN103536606A (en) | Wettable sulfamethoxydiazine powder and preparation method thereof | |
| CN103655540B (en) | Myricetin crystal compound is used for the application of the medicine of nerous sedative | |
| CN105708910A (en) | Preparation method of powder for clearing away heat and toxic materials of livestock and poultry | |
| CN102784136B (en) | Preparation process of compound florfenicol injection for livestock |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150603 Termination date: 20150924 |
|
| EXPY | Termination of patent right or utility model |